"All doses of Mounjaro and Zepbound are listed as available on the FDA's website, consistent with our previous statements that supply would steadily improve toward the latter half of 2024," Reuters added, quoting an Eli Lilly spokesperson. "While we will do our best to support those who want to start taking Wegovy, it is important to recognize that overall demand will continue to exceed supply, and some patients may still have difficulty filling Wegovy prescriptions," Novo Nordisk noted in an update on its website. Meanwhile, Lilly's CEO recently assured that the Zepbound shortage would be resolved "very soon."